Jason S. Starr, DO, discusses DLL3 as a treatment target in extrapulmonary neuroendocrine carcinomas.
Jason Starr, DO
Advertisement
Articles by Jason Starr, DO
Jason Starr, DO, discusses the characterization of POLE/POLD1 mutations in colorectal adenocarcinoma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC
2
FDA Approves Adjuvant Belzutifan Plus Pembrolizumab in ccRCC
3
Subgroup Analyses Confirm Clinically Meaningful Revumenib Responses in AML Across Mutational Profiles
4
Data Support Luspatercept at Maximum-Approved Dose for Transfusion-Dependent Lower-Risk MDS
5